Opinion · 25 Jun 2026
Conference abstractPublished 17 Sep 2012
Identification of potential chemosensitivity genes in multiple myeloma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chemotherapy agents are extremely important in the treatment of liquid malignancies, such as multiple myeloma (MM). Unfortunately, chemotherapy resistance in MM therapy is the most significant cause of treatment failure. The ability to predict, treat, or circumvent resistance is extremely likely to improve clinical outcomes. Thus, identification of novel genes that play a crucial role in MM progression and chemosensitivity is necessary to understand this disease better at the molecular level. Moreover, these genes and their products may serve as new therapeutic targets for MM, whose expression could improve patient outcomes or served as a predictor for chemotherapy outcome. Toward this purpose, we have successfully developed a high-throughput siRNA based functional target validation approach and identified a group of potential chemosensitivity genes. Our preliminary studies focusing on one of the candidate gene, ZO1 (zonula occludens 1), suggested that targeting ZO1 led to tumor cell resistant to several chemotherapy agents, including doxorubicin (Dox), cisplatin (Cis), methotrexate (MTX), and bortezomib. Further analysis with 264 bortezomib treated MM patients indicated that expression level of ZO1 correlated with patient response to bortezomib treatment. RPMI 8226 MM cell line, which were developed against bortezomib treatment in our lab, showed loss of ZO1 expression, suggesting a role of ZO1 may play in bortezomib resistance development. More importantly, ZO1 targeting in myeloma cells resulted in cell resistance to bortezomib treatment. Taken together, these studies revealed a novel chemosensitivity gene ZO1, which may form a basis for algorithms to help predict chemosensitivity based on baseline gene expression profiles in the future, and may provide the strategies aimed at enhancing chemosensitivity by increasing expression of target genes of interest.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Translational Medicine.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Lin Yang”
